Highcroft Veterinary Referrals, CVS Group, Bristol, United Kingdom.
Langford Vets, University of Bristol, Bristol, United Kingdom.
J Vet Intern Med. 2022 May;36(3):877-885. doi: 10.1111/jvim.16403. Epub 2022 Mar 18.
Beta-blockade is sometimes used in dogs with pulmonic stenosis with the intent of reducing frequency of ventricular arrhythmias during right heart catheterization.
To evaluate if pretreatment with atenolol reduces frequency of ventricular arrhythmias, anesthetist interventions, or shortens procedure time.
Thirty dogs with pulmonic stenosis scheduled for interventional procedures.
Single center, prospective, randomized, open-label study. Dogs were randomized to treatment with atenolol or no treatment preoperatively for a minimum of 10 days. Variables recorded included heart rate, arrhythmias and complexity, total procedure time and administration of antiarrhythmic treatment, vasopressors, positive chronotropes, or fluid boluses.
Fifteen dogs were enrolled in each group. Dogs receiving atenolol had lower mean heart rates during the procedure (atenolol 100 ± 11 bpm vs untreated 115 ± 19 bpm, P = .01). There were no significant differences between the atenolol and untreated groups in the frequency of ventricular ectopic complexes (535 [6-5296] vs 553 [79-2863], P = .9), ventricular couplets (46 [0-481] vs 29 [3-121], P = .59), ventricular triplets (20 [0-265] vs 16 [1-82], P = .67), ventricular tachycardia (8 [0-224] vs 8 [1-118], P = .99), proportion exhibiting R-on-T phenomenon (11/15 vs 14/15, P = .33), proportion receiving intraoperative lidocaine (1/15 vs 3/15, P = .6), vasopressors/positive chronotropes (11/15 vs 5/15, P = .06), or fluid boluses (12/15 vs 7/15, P = .13). The procedure time was similar (atenolol 41 [23-68] min vs untreated 35 [18-98] min, P = .91).
No benefit of preoperative atenolol treatment was identified in this small group of dogs.
在患有肺动脉瓣狭窄的犬中，有时会使用β受体阻滞剂，以期减少右心导管检查时室性心律失常的发生频率。
评估普萘洛尔预处理是否能减少室性心律失常的发生频率、麻醉师的干预或缩短手术时间。
30 只患有肺动脉瓣狭窄的犬，计划进行介入治疗。
单中心、前瞻性、随机、开放标签研究。将犬随机分为术前接受普萘洛尔治疗组或不治疗组，至少治疗 10 天。记录的变量包括心率、心律失常的频率和复杂性、总手术时间以及抗心律失常药物、血管加压药、正性变力药或液体冲击疗法的使用情况。
每组有 15 只犬入组。接受普萘洛尔治疗的犬在手术过程中的平均心率较低（普萘洛尔组 100±11bpm 与未治疗组 115±19bpm，P=0.01）。普萘洛尔组和未治疗组在室性期前收缩的频率（535[6-5296]与 553[79-2863]，P=0.9）、室性成对搏动的频率（46[0-481]与 29[3-121]，P=0.59）、室性三联律的频率（20[0-265]与 16[1-82]，P=0.67）、室性心动过速的频率（8[0-224]与 8[1-118]，P=0.99）、表现出 R-on-T 现象的比例（11/15 与 14/15，P=0.33）、术中使用利多卡因的比例（1/15 与 3/15，P=0.6）、血管加压药/正性变力药的使用比例（11/15 与 5/15，P=0.06）或液体冲击疗法的使用比例（12/15 与 7/15，P=0.13）方面无显著差异。手术时间相似（普萘洛尔组 41[23-68]min 与未治疗组 35[18-98]min，P=0.91）。
在这一小组犬中，术前使用普萘洛尔治疗并未显示出益处。
